Objective: To examine the impact of nephrectomy delay on the survival of patients with small renal masses. Methods: Relying on the Surveillance, Epidemiology, and End Results Medicare-linked database, 6,237 patients with pT1a renal cell carcinoma who underwent radical or partial nephrectomy were identified (1988-2005). Nephrectomy delay was dichotomized as ≤3 vs. >3 months. Uni- and multivariate Cox regression analyses tested the effect of delayed nephrectomy on cancer-specific mortality (CSM). In sub-analyses, various other time from diagnosis to nephrectomy cut-offs were modelled: (a) ≤1 vs. >1 month, (b) ≤2 vs. >2 months, (c) ≤4 vs. >4 months, (d) ≤6 vs. >6 months, (e) ≤12 vs. >12 months or (f) continuously coded. Results: In univariate analyses, nephrectomy delay >3 months was associated with a higher risk of CSM (hazard ratio [HR]: 2.07; 95% confidence interval [CI]: 1.58-2.72; p < 0.001). However, after multivariate adjustment, a nephrectomy delay >3 months was not significantly associated with a higher risk of CSM (HR: 1.33; 95% CI: 0.96-1.86; p = 0.09). The lack of a relationship between nephrectomy delay and CSM after multivariate adjustment persisted even in various sub-analyses of other categorizations for nephrectomy delay. Conclusions: In the case of eventual nephrectomy delay among patients with small renal masses, CSM is unaffected.

Keywords:
Renal cell carcinoma, Nephrectomy, Observation, Treatment delay, Survival
1.
Sun M, Thuret R, Abdollah F, et al: Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol 2011;59:135-141.
2.
Doeuk N, Guo DY, Haddad R, et al: Renal cell carcinoma: stage, grade and histology migration over the last 15 years in a large Australian surgical series. BJU Int 2011;107:1381-1385.
3.
Campbell SC, Novick AC, Belldegrun A, et al: Guideline for management of the clinical T1 renal mass. J Urol 2009;182:1271-1279.
4.
Abou Youssif T, Kassouf W, Steinberg J, Aprikian AG, Laplante MP, Tanguay S: Active surveillance for selected patients with renal masses: updated results with long-term follow-up. Cancer 2007;110:1010-1014.
5.
Abouassaly R, Lane BR, Novick AC: Active surveillance of renal masses in elderly patients. J Urol 2008;180:505-508; discussion 508-509.
6.
Crispen PL, Viterbo R, Fox EB, Greenberg RE, Chen DY, Uzzo RG: Delayed intervention of sporadic renal masses undergoing active surveillance. Cancer 2008;112:1051-1057.
7.
Heuer R, Gill IS, Guazzoni G, et al: A critical analysis of the actual role of minimally invasive surgery and active surveillance for kidney cancer. Eur Urol 2010;57:223-232.
8.
Patel N, Cranston D, Akhtar MZ, et al: Active surveillance of small renal masses offers short-term oncological efficacy equivalent to radical and partial nephrectomy. BJU Int 2012;110:1270-1275.
9.
Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG: The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol 2006;175:425-431.
10.
Jewett MA, Mattar K, Basiuk J, et al: Active surveillance of small renal masses: progression patterns of early stage kidney cancer. Eur Urol 2011;60:39-44.
11.
Crispen PL, Viterbo R, Boorjian SA, Greenberg RE, Chen DY, Uzzo RG: Natural history, growth kinetics, and outcomes of untreated clinically localized renal tumors under active surveillance. Cancer 2009;115:2844-2852.
12.
Smaldone MC, Kutikov A, Egleston BL, et al: Small renal masses progressing to metastases under active surveillance: a systematic review and pooled analysis. Cancer 2012;118:997-1006.
13.
Remzi M, Ozsoy M, Klingler HC, et al: Are small renal tumors harmless? Analysis of histopathological features according to tumors 4 cm or less in diameter. J Urol 2006;176:896-899.
14.
Kunkle DA, Crispen PL, Chen DY, Greenberg RE, Uzzo RG: Enhancing renal masses with zero net growth during active surveillance. J Urol 2007;177:849-853; discussion 853-854.
15.
Hankey BF, Ries LA, Edwards BK: The surveillance, epidemiology, and end results program: a national resource. Cancer Epidemiol Biomarkers Prev 1999;8:1117-1121.
16.
Engels EA, Pfeiffer RM, Ricker W, Wheeler W, Parsons R, Warren JL: Use of surveillance, epidemiology, and end results-medicare data to conduct case-control studies of cancer among the US elderly. Am J Epidemiol 2011;174:860-870.
17.
Rais-Bahrami S, Guzzo TJ, Jarrett TW, Kavoussi LR, Allaf ME: Incidentally discovered renal masses: oncological and perioperative outcomes in patients with delayed surgical intervention. BJU Int 2009;103:1355-1358.
18.
Stec AA, Coons BJ, Chang SS, et al: Waiting time from initial urological consultation to nephrectomy for renal cell carcinoma - does it affect survival? J Urol 2008;179:2152-2157.
19.
Klabunde CN, Potosky AL, Legler JM, Warren JL: Development of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-1267.
20.
Sun M, Abdollah F, Liberman D, et al: Racial disparities and socioeconomic status in men diagnosed with testicular germ cell tumors: a survival analysis. Cancer 2011;117:4277-4285.
21.
Beisland C, Hjelle KM, Reisaeter LA, Bostad L: Observation should be considered as an alternative in management of renal masses in older and comorbid patients. Eur Urol 2009;55:1419-1427.
22.
Ljungberg B, Cowan NC, Hanbury DC, et al: EAU guidelines on renal cell carcinoma: the 2010 update. Eur Urol 2010;58:398-406.
23.
Lane BR, Abouassaly R, Gao T, et al: Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer 2010;116:3119-3126.
24.
Sun M, Becker A, Tian Z, Roghmann F, Abdollah F, Larouche A, Karakiewicz PI, Trinh QD: Management of localized kidney cancer: calculating cancer-specific mortality and competing risks of death for surgery and nonsurgical management. Eur Urol 2014;65:235-241.
25.
Tan HJ, Wolf JS Jr, Ye Z, Wei JT, Miller DC: Complications and failure to rescue after laparoscopic versus open radical nephrectomy. J Urol 2011;186:1254-1260.
26.
Yasuda Y, Yuasa T, Yamamoto S, et al: Evaluation of the RENAL nephrometry scoring system in adopting nephron-sparing surgery for cT1 renal cancer. Urol Int 2013;90:179-183.
27.
Becker A, Roghmann F, Trinh QD, Hansen J, Tian Z, Shariat SF, Noldus J, Perrotte P, Graefen M, Karakiewicz PI, Sun M: Sociodemographic disparities in the treatment of small renal masses. BJU Int 2013;111:E274-E282.
28.
Shah JB, Margulis V: In search of a better crystal ball: recent advances in prognostic markers for clear-cell renal cell carcinoma. Expert Rev Anticancer Ther 2010;10:837-842.
29.
de Cassio Zequi S, de Campos ECR, Guimaraes GC, Bachega W Jr, da Fonseca FP, Lopes A: The use of the American Society of Anesthesiology classification as a prognostic factor in patients with renal cell carcinoma. Urol Int 2010;84:67-72.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.